Cullen/Frost Bankers’s Tarsus Pharmaceuticals TARS Stock Holding History

Cullen/Frost Bankers’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	-$421	–	1486
2026 Q1	$421	Buy	+6	New	+$419	﹤0.01%	1335

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cullen/Frost Bankers's TARS Position: Q2 2026 in Review

Cullen/Frost Bankers sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 6 shares — an estimated $421 sold.

Cullen/Frost Bankers first reported a position in TARS in Q1 2026 and held it in 1 quarter. The position peaked at $421 in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Cullen/Frost Bankers reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cullen/Frost Bankers sold 6 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $421.
Cullen/Frost Bankers first reported a position in Tarsus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Cullen/Frost Bankers's Tarsus Pharmaceuticals position peaked at $421 in Q1 2026.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.